Tempus AI, Inc (TEM)
NASDAQ: TEM · Real-Time Price · USD
58.15
+4.18 (7.75%)
At close: Nov 20, 2024, 4:00 PM
58.58
+0.43 (0.73%)
After-hours: Nov 20, 2024, 7:58 PM EST
Tempus AI Revenue
Tempus AI had revenue of $180.93M in the quarter ending September 30, 2024, with 32.98% growth. This brings the company's revenue in the last twelve months to $640.44M, up 32.13% year-over-year. In the year 2023, Tempus AI had annual revenue of $531.82M with 65.85% growth.
Revenue (ttm)
$640.44M
Revenue Growth
+32.13%
P/S Ratio
8.53
Revenue / Employee
$328,095
Employees
1,952
Market Cap
9.16B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
Dec 31, 2019 | 62.06M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Ensign Group | 4.11B |
Bruker | 3.24B |
Bio-Rad Laboratories | 2.58B |
Bio-Rad Laboratories | 2.58B |
Chemed | 2.38B |
Masimo | 2.04B |
HealthEquity | 1.10B |
Intra-Cellular Therapies | 613.73M |
TEM News
- 8 days ago - Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation - Seeking Alpha
- 8 days ago - Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR® - Business Wire
- 9 days ago - Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care - Business Wire
- 11 days ago - Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting - Business Wire
- 13 days ago - Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test - Business Wire
- 16 days ago - Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics - Business Wire
- 17 days ago - Tempus to Report Third Quarter 2024 Financial Results on November 4 - Business Wire